PRESS RELEASE published on 05/31/2024 at 15:51, 1 year 10 months ago DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies announces plan to change ADS Ratio to regain Nasdaq compliance effective June 7th, 2024, impacting ADS holders trading price Biopharmaceutical Company Nasdaq Compliance DBV Technologies ADS Ratio Change Food Allergies Treatment
BRIEF published on 05/17/2024 at 22:35, 1 year 10 months ago DBV Technologies Announces ADS Ratio Change Nasdaq Compliance Biopharmaceuticals Stock Adjustment DBV Technologies ADS Ratio Change
PRESS RELEASE published on 05/17/2024 at 22:30, 1 year 10 months ago DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies announces plan to change ADS Ratio to regain Nasdaq compliance. The ADS Ratio Change will be effective on June 3rd, 2024, impacting ADS trading price. No impact on underlying ordinary shares Ordinary Shares Nasdaq Compliance DBV Technologies ADS Ratio Change Trading Price
BRIEF published on 05/16/2024 at 22:35, 1 year 10 months ago DBV Technologies announces the results of the 2024 Combined General Meeting General Assembly 2024 DBV Technologies Resolutions Adopted Allergy Treatment Biopharmaceutical Sector
PRESS RELEASE published on 05/16/2024 at 22:30, 1 year 10 months ago DBV Technologies Announces Results of its 2024 Combined General Meeting DBV Technologies announces successful results of its 2024 Combined General Meeting where shareholders approved all proposed resolutions. The Company focuses on treatment options for food allergies Resolutions Combined General Meeting DBV Technologies Food Allergies Treatment Options
BRIEF published on 05/09/2024 at 22:35, 1 year 10 months ago DBV Technologies announces its participation in two investor conferences in May DBV Technologies Food Allergy JMP Life Sciences HC Wainwright BioConnect Conference Webcast
PRESS RELEASE published on 05/09/2024 at 22:30, 1 year 10 months ago DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies to participate in two upcoming investor conferences in May, presenting its clinical-stage biopharmaceutical developments. Learn more about their innovative treatment options Investor Conferences Biopharmaceutical DBV Technologies Food Allergies Immunologic Conditions
BRIEF published on 05/07/2024 at 22:35, 1 year 11 months ago DBV Technologies publishes its financial results for the first quarter of 2024 and provides an update on its activities DBV Technologies Financial Results Effectiveness Viaskin Peanut Regulatory Affairs Appointment Cash Flow Evolution VITESSE Clinical Trial
PRESS RELEASE published on 05/07/2024 at 22:30, 1 year 11 months ago DBV Technologies Reports First Quarter 2024 Financial Results and Business Update DBV Technologies reports Q1 2024 financial results and business update, with VITESSE enrollment progress, appointment of Chief Regulatory Officer, and $101.5 million cash balance Financial Results Q1 2024 DBV Technologies VITESSE Enrollment Chief Regulatory Officer
Published on 04/08/2026 at 14:30, 1 hour 53 minutes ago Goldcliff Confirms Free Gold at Kettle Valley North Cliff Zone, Assays up to 2.70 g/t Au and 29.2 g/t Ag
Published on 04/08/2026 at 14:30, 1 hour 53 minutes ago Datametrex Enters Strategic Agreement with Hilco Global to Advance Patent Monetization
Published on 04/08/2026 at 14:30, 1 hour 53 minutes ago Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Published on 04/08/2026 at 14:22, 2 hours 1 minute ago CBMJ Completes Patriot.TV Asset Sale, Reduces Capital Requirements and Accelerates Path Toward Contemplated Strategic Acquisition
Published on 04/08/2026 at 15:55, 28 minutes ago Abilitie, TED, and St. Edward's University launch 12-week mini-MBA
Published on 04/08/2026 at 15:13, 1 hour 10 minutes ago Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc
Published on 04/08/2026 at 15:12, 1 hour 11 minutes ago Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 04/08/2026 at 15:11, 1 hour 12 minutes ago Form 8.3 - The Vanguard Group, Inc.: British Land Company plc, The
Published on 04/08/2026 at 12:58, 3 hours 24 minutes ago EURAZEO IS ASSIGNED A BBB CREDIT RATING (STABLE OUTLOOK) BY S&P AND A BBB CREDIT RATING (STABLE OUTLOOK) BY FITCH
Published on 04/08/2026 at 11:00, 5 hours 23 minutes ago MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 04/08/2026 at 10:17, 6 hours 6 minutes ago BBB LONG-TERM CREDIT RATING WITH A STABLE OUTLOOK EXPECTED FOR EURAZEO FROM BOTH S&P AND FITCH
Published on 04/08/2026 at 08:30, 7 hours 53 minutes ago Edenred Mobility and Electra form a strategic partnership to accelerate the electrification of commercial fleets in France
Published on 04/07/2026 at 17:57, 22 hours 26 minutes ago Peugeot Invest publishes its 2025 Universal Registration Document
